Showing results (71-80 of 204) with videos related to
Sort By:
Pageof 21
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small, Andrew D Zelenetz, Ariela Noy, et al.Health and Quality of Life Outcomes|November 16, 2019
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trialMarco Montillo, Árpád Illés, Tadeusz Robak, et al.Haematologica|July 9, 2016
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planesAnita Kumar, Irene A Burger, Zhigang Zhang, et al.Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyCarla Casulo, Michelle Byrtek, Keith L Dawson, et al.Blood|January 24, 2004
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani, Andrew D Zelenetz, Stephen D Nimer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|March 1, 2003
MUC-1 mucin protein expression in B-cell lymphomasJulie Teruya-Feldstein, Gerard B Donnelly, Andre Goy, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell LymphomaHeiko Schöder, Andrew D Zelenetz, Paul Hamlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Follicular lymphoma in the United States: first report of the national LymphoCare studyJonathan W Friedberg, Michael D Taylor, James R Cerhan, et al.Pageof 21